Novo takes over three Catalent fill plants to make more pens
After a long antitrust review, Novo Holdings closed its purchase of Catalent and handed three filling plants to Novo Nordisk, the maker of Wegovy and Ozempic.
Who feels it
-
Sellers
Rethink
Rivals lose access to some contract filling capacity they had used.
-
Patients
Worth knowing
No change today; the payoff is more pens over the next few years.
-
Prescribers
Worth knowing
Fewer gaps in supply should mean fewer forced switches between doses.
-
Pharmacies
Worth knowing
Steadier supply makes stocking easier, but not right away.
-
Payers
Worth knowing
More supply weakens the case for paying for compounded stopgaps.
The deal
Novo Holdings, the foundation-controlled investor, bought the contract manufacturer Catalent. It then sold three of Catalent’s fill-finish sites to Novo Nordisk. The deal closed in December 2024 after review by competition authorities.
Why filling matters
For injectable medicines, the bottleneck is often not the drug itself but the last step: filling it into pens and packing it. During the shortage years, this step limited how many pens reached pharmacies.
Who notices
- Sellers feel it first. Other drug companies used Catalent sites, and some worried about access.
- Patients and pharmacies notice later, if supply gaps shrink.
The open question
Turning a plant over to a new product takes validation and inspection. The benefit is spread over years, not weeks.
Source Novo Holdings and Novo Nordisk announcements on the Catalent transaction, December 2024
Spotted an error? Tell us through the contact form; we follow the corrections policy.
